Fluorodopa (¹⁸F)

Fluorodopa (¹⁸F)
Clinical data
Trade names	Fluorodopa F18
Other names	6-fluoro-L-DOPA, FDOPA
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US DailyMed: Fluorodopa;
Routes of; administration	Intravenous
ATC code	V09IX05 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (2S)-2-amino-3-(2-(18F)fluoranyl-4,5-dihydroxyphenyl)propanoic acid;
CAS Number	92812-82-3;
PubChem CID	56494;
DrugBank	DB13848;
ChemSpider	50970;
UNII	2C598205QX;
KEGG	D04220;
ChEBI	CHEBI:49166;
ChEMBL	ChEMBL3400972;
CompTox Dashboard (EPA)	DTXSID90226257 ;
Chemical and physical data
Formula	C9H10FNO4
Molar mass	215.180 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=C(C(=CC(=C1O)O)F)CC(C(=O)O)N;
	InChI InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1; Key:PAXWQORCRCBOCU-RPDRGXCHSA-N;

Fluorodopa (¹⁸F), also known as FDOPA, is a fluorinated form of L-DOPA primarily synthesized as its fluorine-18 isotopologue for use as a radiotracer in positron emission tomography (PET).^[2]

The most common side effects are injection site pain.^[1]

Medical uses

Fluorodopa (¹⁸F) is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adults with suspected Parkinsonian syndromes.^[1]

History

In October 2019, Fluorodopa (¹⁸F) was approved in the United States for the visual detection of certain nerve cells in adults with suspected Parkinsonian syndromes.^[3]^[4]

The US Food and Drug Administration approved Fluorodopa F 18 based on evidence from one clinical trial of 56 participants with suspected Parkinsonian syndromes.^[3] The trial was conducted at one clinical site in the United States.^[3]

References

^ ^a ^b ^c "Fluorodopa F18 injection". DailyMed. 12 October 2019. Retrieved 26 April 2020.
^ Deng WP, Wong KA, Kirk KL (June 2002). "Convenient syntheses of 2-, 5- and 6-fluoro- and 2,6-difluoro-L-DOPA". Tetrahedron: Asymmetry. 13 (11): 1135–1140. doi:10.1016/S0957-4166(02)00321-X.
^ ^a ^b ^c "Drug Trials Snapshots: Fluorodopa F 18". U.S. Food and Drug Administration (FDA). 27 November 2019. Archived from the original on 27 November 2019. Retrieved 27 November 2019. This article incorporates text from this source, which is in the public domain.
^ "Drug Approval Package: Fluorodopa F18". U.S. Food and Drug Administration (FDA). 20 November 2019. Archived from the original on 27 November 2019. Retrieved 26 November 2019. This article incorporates text from this source, which is in the public domain.

[Fluorodopa_F18_FDA_label-1] "Fluorodopa F18 injection". DailyMed. 12 October 2019. Retrieved 26 April 2020.

[Deng_2002-2] Deng WP, Wong KA, Kirk KL (June 2002). "Convenient syntheses of 2-, 5- and 6-fluoro- and 2,6-difluoro-L-DOPA". Tetrahedron: Asymmetry. 13 (11): 1135–1140. doi:10.1016/S0957-4166(02)00321-X.

[FDA_Snapshot-3] "Drug Trials Snapshots: Fluorodopa F 18". U.S. Food and Drug Administration (FDA). 27 November 2019. Archived from the original on 27 November 2019. Retrieved 27 November 2019. This article incorporates text from this source, which is in the public domain.

[4] "Drug Approval Package: Fluorodopa F18". U.S. Food and Drug Administration (FDA). 20 November 2019. Archived from the original on 27 November 2019. Retrieved 26 November 2019. This article incorporates text from this source, which is in the public domain.

[1]

[2]

[3]

[4]